Jeng-Shin Lee
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeng-Shin Lee.
Nature | 2004
Laising Yen; Jennifer Svendsen; Jeng-Shin Lee; John T. Gray; Maxime Magnier; Takashi Baba; Robert J. D'Amato; Richard C. Mulligan
Recent studies on the control of specific metabolic pathways in bacteria have documented the existence of entirely RNA-based mechanisms for controlling gene expression. These mechanisms involve the modulation of translation, transcription termination or RNA self-cleavage through the direct interaction of specific intracellular metabolites and RNA sequences. Here we show that an analogous RNA-based gene regulation system can effectively be designed for mammalian cells via the incorporation of sequences encoding self-cleaving RNA motifs into the transcriptional unit of a gene or vector. When correctly positioned, the sequences lead to potent inhibition of gene or vector expression, owing to the spontaneous cleavage of the RNA transcript. Administration of either oligonucleotides complementary to regions of the self-cleaving motif or a specific small molecule results in the efficient induction of gene expression, owing to inhibition of self-cleavage of the messenger RNA. Efficient regulation of transgene expression is shown in a variety of mammalian cell lines and live animals. In conjunction with other emerging technologies, this methodology may be particularly applicable to the development of gene regulation systems tailored to any small inducer molecule, and provide a novel means of biological sensing in vivo that may have an important application in the regulated delivery of protein therapeutics.
Nature Medicine | 2006
Betty Y. Y. Tam; Kevin Wei; John S. Rudge; Jana Hoffman; Joceyln Holash; Sang-ki Park; Jenny Yuan; Colleen Hefner; Cecile Chartier; Jeng-Shin Lee; Shelly Jiang; Nihar R. Nayak; Frans A. Kuypers; Lisa Ma; Uma Sundram; Grace Wu; Joseph A. Garcia; Stanley L. Schrier; Jacquelyn J. Maher; Randall S. Johnson; George D. Yancopoulos; Richard C. Mulligan; Calvin J. Kuo
Vascular endothelial growth factor (VEGF) exerts crucial functions during pathological angiogenesis and normal physiology. We observed increased hematocrit (60–75%) after high-grade inhibition of VEGF by diverse methods, including adenoviral expression of soluble VEGF receptor (VEGFR) ectodomains, recombinant VEGF Trap protein and the VEGFR2-selective antibody DC101. Increased production of red blood cells (erythrocytosis) occurred in both mouse and primate models, and was associated with near-complete neutralization of VEGF corneal micropocket angiogenesis. High-grade inhibition of VEGF induced hepatic synthesis of erythropoietin (Epo, encoded by Epo) >40-fold through a HIF-1α–independent mechanism, in parallel with suppression of renal Epo mRNA. Studies using hepatocyte-specific deletion of the Vegfa gene and hepatocyte–endothelial cell cocultures indicated that blockade of VEGF induced hepatic Epo by interfering with homeostatic VEGFR2-dependent paracrine signaling involving interactions between hepatocytes and endothelial cells. These data indicate that VEGF is a previously unsuspected negative regulator of hepatic Epo synthesis and erythropoiesis and suggest that levels of Epo and erythrocytosis could represent noninvasive surrogate markers for stringent blockade of VEGF in vivo.NOTE: In the version of this article initially published, the name of one of the authors, Nihar R. Nayak, was misspelled as Nihar R. Niyak. The error has been corrected in the HTML and PDF versions of the article.
Journal of Clinical Investigation | 2013
Ute E. Burkhardt; Ursula Hainz; Kristen E. Stevenson; Natalie R. Goldstein; Mildred Pasek; Masayasu Naito; Di Wu; Vincent T. Ho; Anselmo Alonso; Naa Norkor Hammond; Jessica C. Wong; Quinlan L. Sievers; Ana Brusic; Sean McDonough; Wanyong Zeng; Ann Perrin; Jennifer R. Brown; Christine Canning; John Koreth; Corey Cutler; Philippe Armand; Donna Neuberg; Jeng-Shin Lee; Joseph H. Antin; Richard C. Mulligan; Tetsuro Sasada; Jerome Ritz; Robert J. Soiffer; Glenn Dranoff; Edwin P. Alyea
BACKGROUND Patients with advanced hematologic malignancies remain at risk for relapse following reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT). We conducted a prospective clinical trial to test whether vaccination with whole leukemia cells early after transplantation facilitates the expansion of leukemia-reactive T cells and thereby enhances antitumor immunity. METHODS We enrolled 22 patients with advanced chronic lymphocytic leukemia (CLL), 18 of whom received up to 6 vaccines initiated between days 30 and 45 after transplantation. Each vaccine consisted of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. Serial patient PBMC samples following transplantation were collected, and the impact of vaccination on T cell activity was evaluated. RESULTS At a median follow-up of 2.9 (range, 1-4) years, the estimated 2-year progression-free and overall survival rates of vaccinated subjects were 82% (95% CI, 54%-94%) and 88% (95% CI, 59%-97%), respectively. Although vaccination only had a modest impact on recovering T cell numbers, CD8+ T cells from vaccinated patients consistently reacted against autologous tumor, but not alloantigen-bearing recipient cells with increased secretion of the effector cytokine IFN-γ, unlike T cells from nonvaccinated CLL patients undergoing allo-HSCT. Further analysis confirmed that 17% (range, 13%-33%) of CD8+ T cell clones isolated from 4 vaccinated patients by limiting dilution of bulk tumor-reactive T cells solely reacted against CLL-associated antigens. CONCLUSION Our studies suggest that autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allo-HSCT. TRIAL REGISTRATION Clinicaltrials.gov NCT00442130. FUNDING NCI (5R21CA115043-2), NHLBI (5R01HL103532-03), and Leukemia and Lymphoma Society Translational Research Program.
Neurology | 2008
L. Rodino-Klapac; Jeng-Shin Lee; Richard C. Mulligan; K. R. Clark
Background: Alpha-sarcoglycan (α-SG) deficiency (limb-girdle muscular dystrophy [LGMD] type 2D) is the most common form of sarcoglycan-LGMD. No treatment is currently available. Prior studies suggest that overexpression of α-SG via adeno-associated virus (AAV)-mediated gene transfer results in poorly sustained gene expression related to transgene toxicity. These findings potentially preclude gene therapy as a treatment approach for LGMD2D. Methods: The human α-SG gene (hα-SG) was directly transferred to the tibialis anterior muscle of 4- to 5-week-old α-SG KO mice using AAV, type 1. The gene was placed under control of either the ubiquitously expressed cytomegalovirus (CMV) promoter or muscle specific promoters that included desmin, muscle creatine kinase (MCK), and its further modification, truncated MCK (tMCK). Low (3 × 109 vg) and high (3 × 1010 vg) doses of AAV1.hα-SG were administered. Results: Sustained gene expression was observed irrespective of promoters at 6 and 12 weeks post gene transfer. Quantitation of α-SG gene expression by fiber counts yielded similar levels of myofiber transduction for both MCK promoters (60 to 70%), while 34% of fibers were transduced with the DES promoter. There was a trend toward lower expression at the 12-week time point with the CMV promoter. Western blot analysis revealed α-SG overexpression using CMV and both the MCK promoters. Conclusion: Our data demonstrate robust and sustained adeno-associated virus type 1 alpha-sarcoglycan gene expression under control of muscle creatine kinase promoters, without evidence of cytotoxicity. These findings support the use of gene therapy as a potential treatment approach for limb-girdle muscular dystrophy type 2D.
OncoImmunology | 2012
Ana Brusic; Ursula Hainz; Martha Wadleigh; Donna Neuberg; Mei Su; Christine Canning; Daniel J. DeAngelo; Richard Stone; Jeng-Shin Lee; Richard C. Mulligan; Jerome Ritz; Glenn Dranoff; Tetsuro Sasada; Catherine J. Wu
BCR-ABL+ K562 cells hold clinical promise as a component of cancer vaccines, either as bystander cells genetically modified to express immunostimulatory molecules, or as a source of leukemia antigens. To develop a method for detecting T-cell reactivity against K562 cell-derived antigens in patients, we exploited the dendritic cell (DC)-mediated cross-presentation of proteins generated from apoptotic cells. We used UVB irradiation to consistently induce apoptosis of K562 cells, which were then fed to autologous DCs. These DCs were used to both stimulate and detect antigen-specific CD8+ T-cell reactivity. As proof-of-concept, we used cross-presented apoptotic influenza matrix protein-expressing K562 cells to elicit reactivity from matrix protein-reactive T cells. Likewise, we used this assay to detect increased anti-CML antigen T-cell reactivity in CML patients that attained long-lasting clinical remissions following immunotherapy (donor lymphocyte infusion), as well as in 2 of 3 CML patients vaccinated with lethally irradiated K562 cells that were modified to secrete high levels of granulocyte macrophage colony-stimulating factor (GM-CSF). This methodology can be readily adapted to examine the effects of other whole tumor cell-based vaccines, a scenario in which the precise tumor antigens that stimulate immune responses are unknown.
Cancer Gene Therapy | 2011
Frank Schwenter; S Zarei; P Luy; V Padrun; N Bouche; Jeng-Shin Lee; Richard C. Mulligan; Philippe Morel; Nicolas Mach
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant in autologous cell-based anti-tumor immunotherapy has recently been approved for clinical application. To avoid the need for individualized processing of autologous cells, we developed a novel strategy based on the encapsulation of GM-CSF-secreting human allogeneic cells. GM-CSF-producing K562 cells showed high, stable and reproducible cytokine secretion when enclosed into macrocapsules. For clinical development, the cryopreservation of these devices is critical. Thawing of capsules frozen at different time points displayed differences in GM-CSF release shortly after thawing. However, similar secretion values to those of non-frozen control capsules were obtained 8 days after thawing at a rate of >1000 ng GM-CSF per capsule every 24 h. For future human application, longer and reinforced capsules were designed. After irradiation and cryopreservation, these capsules produced >300 ng GM-CSF per capsule every 24 h 1 week after thawing. The in vivo implantation of encapsulated K562 cells was evaluated in mice and showed preserved cell survival. Finally, as a proof of principle of biological activity, capsules containing B16-GM-CSF allogeneic cells implanted in mice induced a prompt inflammatory reaction. The ability to reliably achieve high adjuvant release using a standardized procedure may lead to a new clinical application of GM-CSF in cell-based cancer immunization.
Molecular Therapy | 2005
Gustavo Mostoslavsky; Darrell N. Kotton; Attila J. Fabian; John T. Gray; Jeng-Shin Lee; Richard C. Mulligan
Transplant Immunology | 2004
Justin R. Fernandes; Valérie F. Duvivier-Kali; Mitchell Keegan; Jennifer Hollister-Lock; Abdulkadir Omer; Stacey Su; Susan Bonner-Weir; Sandy Feng; Jeng-Shin Lee; Richard C. Mulligan; Gordon C. Weir
Archive | 1999
John T. Gray; Jeng-Shin Lee; Richard C. Mulligan
Nature Medicine | 2009
Betty Y. Y. Tam; Kevin Wei; John S. Rudge; Jana Hoffman; Joceyln Holash; Sang-ki Park; Jenny Yuan; Colleen Hefner; Cecile Chartier; Jeng-Shin Lee; Shelly Jiang; Nihar R. Nayak; Frans A. Kuypers; Lisa Ma; Uma Sundram; Grace Wu; Joseph A. Garcia; Stanley L. Schrier; Jacquelyn J. Maher; Randall S. Johnson; George D. Yancopoulos; Richard C. Mulligan; Calvin J. Kuo